Last $1.70 USD
Change Today +0.08 / 4.94%
Volume 3.0M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Open
$1.63
Previous Close
$1.62
Day High
$1.72
Day Low
$1.62
52 Week High
01/22/14 - $8.41
52 Week Low
09/16/14 - $1.60
Market Cap
331.7M
Average Volume 10 Days
4.8M
EPS TTM
$-1.27
Shares Outstanding
195.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

227 Employees
Last Reported Date: 02/20/14
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $681.7K
Executive Vice President
Total Annual Compensation: $617.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $577.3K
Consultant
Total Annual Compensation: $689.2K
Compensation as of Fiscal Year 2013.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Cuts Workforce by 70%

Exelixis, Inc. announced that the company will reduce its workforce by 70%, or approximately 160 employees, resulting in approximately 70 remaining employees.

Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer

Exelixis, Inc. announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for patients treated with cabozantinib as compared to prednisone. The median OS for the cabozantinib arm of the trial was 11.0 months versus 9.8 months for the prednisone arm (hazard ratio 0.90; 95% confidence interval 0.76 -- 1.06; p value 0.212). The COMET-1 results are the subject of ongoing analyses. Exelixis will submit additional data, including secondary and exploratory endpoints, for presentation at a future medical conference. Besides OS, the exploratory endpoint of progression-free survival (PFS) as assessed by the investigators is the only time-to-event-based endpoint for which data are available. Median PFS was 5.5 months for the cabozantinib arm of the trial versus 2.8 months for the prednisone arm (hazard ratio 0.50; 95% confidence interval 0.42 -- 0.60; p value <0.0001). Safety data were consistent with those observed in earlier-stage trials of cabozantinib in mCRPC.

Exelixis, Inc. - Special Call

To discuss the COMET-1 top-line results and the resulting corporate initiatives

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $1.70 USD +0.08

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.78 USD +0.02
CTI BioPharma Corp $2.79 USD +0.28
Curis Inc $1.56 USD -0.01
Cytokinetics Inc $3.87 USD +0.12
Rigel Pharmaceuticals Inc $2.20 USD -0.03
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.8x
Price/Book 97.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit www.exelixis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.